RAMONA BALL: Open Payments
NPI 1578010088 · JACKSON, MS. Company-reported industry payments from CMS Open Payments. A payment does not imply wrongdoing.
See the full provider profile for registry, prescribing and billing details.
Industry payments (Sunshine Act)
Source: CMS Open Payments general payments. Payments from drug and device companies are reported by the companies; they do not imply wrongdoing and are separate from Medicare billing.
$2,245 in 111 payments from 38 companies in 2025. Trend: 2023 $1,671 · 2024 $2,293 · 2025 $2,245
Food & beverage: $2,245
| Company | Payments | Amount |
|---|---|---|
| Novartis Pharmaceuticals Corporation | 15 | $259 |
| Merck Sharp & Dohme LLC | 9 | $166 |
| TerSera Therapeutics LLC | 6 | $163 |
| Genentech USA, Inc. | 8 | $159 |
| Janssen Biotech, Inc. | 9 | $155 |
| Celgene Corporation | 5 | $126 |
| Astellas Pharma US Inc | 5 | $91 |
| PFIZER INC. | 4 | $89 |
| Gilead Sciences, Inc. | 3 | $86 |
| E.R. Squibb & Sons, L.L.C. | 4 | $84 |
Products named: Zoladex, KISQALI, KEYTRUDA, REBLOZYL, Trodelvy, OPDIVO, Vyloy, Orserdu.
Industry payments across MS — which companies pay providers there.
